Matthias J E Arlt
Overview
Explore the profile of Matthias J E Arlt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
537
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mazumdar A, Urdinez J, Boro A, Arlt M, Egli F, Niederost B, et al.
Cancers (Basel)
. 2020 Nov;
12(11).
PMID: 33233625
The pre-metastatic niche (PMN) is a tumor-driven microenvironment in distant organs that can foster and support the survival and growth of disseminated tumor cells. This facilitates the establishment of secondary...
2.
Mazumdar A, Urdinez J, Boro A, Migliavacca J, Arlt M, Muff R, et al.
Int J Mol Sci
. 2020 Aug;
21(15).
PMID: 32751693
Tumor-secreted extracellular vesicles (EVs) have been identified as mediators of cancer-host intercellular communication and shown to support pre-metastatic niche formation by modulating stromal cells at future metastatic sites. While osteosarcoma,...
3.
Cambria E, Arlt M, Wandel S, Krupkova O, Hitzl W, Passini F, et al.
Cells
. 2020 Jul;
9(7).
PMID: 32708074
Mechanical loading and inflammation interact to cause degenerative disc disease and low back pain (LBP). However, the underlying mechanosensing and mechanotransductive pathways are poorly understood. This results in untargeted pharmacological...
4.
Neklyudova O, Arlt M, Brennecke P, Thelen M, Gvozdenovic A, Kuzmanov A, et al.
J Cancer Res Clin Oncol
. 2016 Jun;
142(8):1739-50.
PMID: 27300512
Purpose: Better understanding of the molecular mechanisms of metastasis-the major cause of death in osteosarcoma (OS)-is a key for the development of more effective metastasis-suppressive therapy. Here, we investigated the...
5.
Brennecke P, Arlt M, Campanile C, Husmann K, Gvozdenovic A, Apuzzo T, et al.
Clin Exp Metastasis
. 2014 Jan;
31(3):339-49.
PMID: 24390633
Current combined surgical and neo-adjuvant chemotherapy of primary metastatic osteosarcoma (OS) is ineffective, reflected by a 5-year survival rate of affected patients of less than 20 %. Studies in experimental...
6.
Arlt M, Banke I, Bertz J, Kumar R, Muff R, Born W, et al.
Sarcoma
. 2013 Dec;
2013:404962.
PMID: 24369449
Metastasis is the major cause of death of osteosarcoma patients and its diagnosis remains difficult. In preclinical studies, however, forced expression of reporter genes in osteosarcoma cells has remarkably improved...
7.
Brennecke P, Arlt M, Muff R, Campanile C, Gvozdenovic A, Husmann K, et al.
PLoS One
. 2013 Sep;
8(9):e74045.
PMID: 24040160
More effective treatment of metastasizing osteosarcoma with a current mean 5-year survival rate of less than 20% requires more detailed knowledge on mechanisms and key regulatory molecules of the complex...
8.
Campanile C, Arlt M, Kramer S, Honer M, Gvozdenovic A, Brennecke P, et al.
J Nucl Med
. 2013 Jun;
54(8):1362-8.
PMID: 23801674
Unlabelled: The aim of this study was to characterize the different phenotypes of osteosarcoma by PET, comparing the uptake of 3 tracers ((18)F-FDG, (18)F-fluoromisonidazole [(18)F-FMISO], and (18)F-fluoride) in preclinical mouse...
9.
Gvozdenovic A, Arlt M, Campanile C, Brennecke P, Husmann K, Born W, et al.
PLoS One
. 2013 Apr;
8(4):e60329.
PMID: 23565227
Osteosarcoma (OS) is the most frequent primary malignant bone cancer in children and adolescents with a high propensity for lung metastasis. Therefore, it is of great importance to identify molecular...
10.
Sabile A, Arlt M, Muff R, Husmann K, Hess D, Bertz J, et al.
Biochim Biophys Acta
. 2013 Mar;
1832(8):1173-82.
PMID: 23528710
Osteosarcoma (OS) is the most common primary bone malignancy in children and adolescents. More than 30% of patients develop lung metastasis, which is the leading cause of mortality. Recently, the...